Sudhir Agrawal

Girls Incorporated — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

71h-index17.8kcitations443works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

DNA and Nucleic Acid Chemistry(142), Advanced biosensing and bioanalysis techniques(95), RNA Interference and Gene Delivery(94), Immune Response and Inflammation(62), Immunotherapy and Immune Responses(40)

Publications443 total

Retraction Note: Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis
British Journal of Cancer·2025Open Access
Spiffy: Multiplying Diffusion LLM Acceleration via Lossless Speculative Decoding
arXiv (Cornell University)·2025Open Access
VOCABTRIM: Vocabulary Pruning for Efficient Speculative Decoding in LLMs
arXiv (Cornell University)·2025Open Access
Fuzzy Laplace Transform Model to Study the Effect of Buffer and ER Fluxes on Cytosolic Calcium Distribution in Neuron Cell
Innovations in Sustainable Technologies and Computing·2025
AdaEDL: Early Draft Stopping for Speculative Decoding of Large Language Models via an Entropy-based Lower Bound on Token Acceptance Probability
arXiv (Cornell University)·2024Open Access
Adopting prospective antimicrobial stewardship (AMS) practice in high-risk immunosuppressed groups: an urgent call to action in the era of antimicrobial resistance (AMR)
JAC-Antimicrobial Resistance·2024· 5 citedOpen Access
Considerations for Creating the Next Generation of RNA Therapeutics: Oligonucleotide Chemistry and Innate Immune Responses to Nucleic Acids
Nucleic Acid Therapeutics·2024· 3 cited
Supplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
2023Open Access
Data from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
2023Open Access
Supplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
2023Open Access
Supplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
2023Open Access
Supplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
2023Open Access
Supplementary Data from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
2023Open Access
Supplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
2023Open Access
Supplementary Table from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
2023Open Access
Supplementary Data from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
2023Open Access
Data from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
2023Open Access
Supplementary Figure 3 from Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in <i>K</i>-<i>Ras</i> Mutant Colorectal and Pancreatic Cancers
2023Open Access
Supplementary Figure 4 from Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in <i>K</i>-<i>Ras</i> Mutant Colorectal and Pancreatic Cancers
2023Open Access
Supplementary Figure 2 from Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in <i>K</i>-<i>Ras</i> Mutant Colorectal and Pancreatic Cancers
2023Open Access
page 1 of 23Next →

Frequent Co-authors

Ruiwen Zhang(12), Paul C. Zamecnik(8), Ekambar R. Kandimalla(7), Jamal Temsamani(6), Zhiwei Jiang(5), John Goodchild(4), Prem S. Sarin(4), Qiuyan Zhao(4), Zhihong Lu(4), Robert B. Diasio(4), M.P. Civeira(3), W M Galbraith(3), Zhuo Zhang(3), Hui Wang(3), Di Sun(3), Radhakrishnan P. Iyer(3), Julianna Lisziewicz(3), Jin Tang(2), Li Mao(2), Paul J. Schechter(2)